AIM Stock Catalyst: AIM ImmunoTech to Present Pre-Clinical Data on Ampligen for Ebola Treatment

May 27, 2026 · 9:17am ET

Company to share findings at an upcoming scientific conference.

Max move

+155.7%

High of day $0.60

Sparker timei

9:17am ET

AIM · May 27, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

AIM ImmunoTech Inc. (NYSE: AIM) announced it will present pre-clinical data on the potential role of its lead drug, Ampligen, for Ebola virus treatment. The presentation will take place at an upcoming scientific conference.

The company will detail the findings, which explore the efficacy and mechanism of action of Ampligen in treating Ebola. AIM ImmunoTech has a free float of 2,777,828 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time AIM sparks.

Download Sniper App →

Catch the next AIM-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →